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Abstract 
Background: The liver fluke Fasciola gigantica modulates several signaling pathways in infected buffaloes to facilitate 
its survival and establishment of persistent infection. In response to the parasite invasion, buffaloes activate innate 
and adaptive immune responses to counter the parasite infection. To detect new proteins that might be involved 
in the interaction between F. gigantica and the buffaloes, and that also might serve as biomarkers for fasciolosis, we 
used proteomic techniques to study the serum proteome of buffaloes during F. gigantica infection. Here, we used an 
isobaric tags for relative and absolute quantitation (iTRAQ)‑based quantitative proteomic approach to identify serum 
proteins that are differentially expressed in infected buffaloes compared to uninfected control buffaloes. Additionally, 
we applied a parallel reaction monitoring (PRM) assay to validate specific proteins identified by the iTRAQ method.
Results: A total of 313, 459 and 399 proteins were identified at 3, 42 and 70 days post‑infection, respectively; of these 
92, 93 and 138 were differentially abundant proteins. Some of the identified differentially abundant proteins, includ‑
ing complement factor H related 5, complement component C6, complement component C7, amine oxidase, plasma 
serine protease inhibitor and lysozyme, are known to be involved in complement system activation, blood coagula‑
tion, platelet activation, lymphocyte’s adhesion and lysozyme hydrolysis. Analysis of data for all three time points after 
infection identified six significantly upregulated proteins in infected serum that separated infected and uninfected 
buffaloes into distinct clusters. Further PRM analysis confirmed the expression of five proteins, namely MHC class I 
antigen, Beta‑2‑microglobulin, NID2 protein, Fetuin‑B and Fibrinogen gamma‑B chain.
Conclusions: These findings provide novel insights into the serum proteomics signature of buffaloes during F. gigan-
tica infection.
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Background
Fasciolosis, caused by infection with Fasciola gigan-
tica or F. hepatica, is an important parasitic disease 
in tropical and temperate regions, respectively [1, 2]. 
Ungulates and humans become infected via ingestion 
of contaminated water or plants containing metacer-
cariae, leading to adverse health consequences [3]. 
Fasciolosis can cause significant economic losses in 
the agricultural industry [4]. The impact on human 
health is enormous, with ~180 million people at risk of 
infection and 17  million people infected [5]. Fasciola 
infection has been associated with liver fibrosis, cir-
rhosis and cancer in affected individuals [6] and liver 
flukes have been reported in the bile duct of humans 
[7–9]. Current methods to control liver fluke infection 
rely on the use of fasciocidal drugs such as triclaben-
dazole. However, increasing anthelmintic resistance 
has become a major concern [10] and together with 
the lack of a commercial vaccine, makes control of 
liver fluke infection challenging [11]. In order to 
develop better therapeutic strategies that can success-
fully control fasciolosis, it is important to have a full 
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understanding of the molecular mechanisms involved 
in Fasciola interactions with host effector systems.
Other key aspects for efficient liver fluke con-
trol includes offering veterinarians access to better 
diagnostic tools which allow a prompt and accurate 
detection of infection. In this respect, having novel 
biomarkers may add value to current diagnostic tests 
and improve clinical decision making by enabling ear-
lier detection of Fasciola infection. Therefore, iden-
tification of infection-specific molecular changes in 
buffaloes can reveal new biomarkers and advance the 
understanding of the pathogenesis of F. gigantica infec-
tion. Transcriptomic data have been obtained from 
buffalo livers infected with F. gigantica [12]; however, 
mRNA abundance does not necessarily correlate with 
protein abundance [13]. The cytokine dynamics of the 
buffalo’s serum during F. gigantica infection has been 
investigated [14]. However, cytokines appeared to have 
a limited diagnostic value on their own because they 
are general products of the host systemic inflamma-
tory response to cell injury or infection.
In recent years, proteomic technology has devel-
oped rapidly and has been widely applied to identify 
biomarkers in studies, for example, on myocardial 
infarction [15], tuberculosis [16] and F. hepatica infec-
tion [17]. Global proteomic studies are, therefore, of 
great importance for understanding the pathophysi-
ology that underpins infection states, including infec-
tion with F. gigantica. The isobaric tags for relative 
and absolute quantification (iTRAQ) is one of the 
most sensitive proteomics techniques currently used 
to compare protein expression across different bio-
logical conditions [18–20] and infection status [21]. A 
traditional limitation of proteomics techniques is the 
inability to confirm the identity of specific proteins. 
Interestingly, parallel reaction monitoring (PRM) is 
a new mass spectrometry method that is more spe-
cific and sensitive than traditional mass spectrometry 
methods and can detect target proteins [22].
In this study, an iTRAQ-based quantitative prot-
eomic analysis of serum of F. gigantica-infected buffa-
loes was performed to explore dynamic serum protein 
responses of buffaloes towards F. gigantica infection. 
A set of five differentially abundant proteins were fur-
ther validated by PRM analysis. By performing this 
combined quantitative proteomic analysis of serum 
from F. gigantica-infected versus uninfected buffaloes 
(control), we found that F. gigantica infection alters 
several key biological processes and specific proteins. 
Our findings provide a global overview for the buffalo 
serum responses to F. gigantica infection and highlight 
new targets for further investigation.
Methods
Preparation of encysted metacercariae
Eggs of F. gigantica were collected from the gall bladder of 
naturally infected buffaloes slaughtered at local abattoirs 
in Guangxi Zhuang Autonomous Region, PR China. The 
collected eggs were incubated at 29  °C for 11  days. The 
newly hatched miracidia were used to infect Galba per-
via snails (3–5 miracidia per snail) maintained in plastic 
trays for 2 h. The infected snails were incubated in order 
to allow the miracidia to develop to sporocysts, rediae 
and cercariae. After ~6 weeks, cercariae were shed from 
infected snails and harvested on 5 × 5  cm cellophane 
sheets in order to form metacercariae. Encysted metacer-
cariae harvested on cellophane sheets were washed sev-
eral times with phosphate buffered saline (PBS) and used 
to infect buffaloes as described previously [23].
Animals and experimental infection
Twenty-four (8–10-month-old) buffaloes were purchased 
from a water buffalo farm in Guangxi Zhuang Autono-
mous Region, PR China. Animals were randomly divided 
into two groups: (i) uninfected, control group (12 buf-
faloes); and (ii) infected group (12 buffaloes). Animals 
within each group were assigned to 4 subgroups (3 buf-
faloes per group). To ensure that all buffaloes used in the 
study were free of any liver fluke infection, fecal samples 
were examined by sedimentation technique for detection 
of fluke eggs and sera were tested for anti-F. gigantica IgG 
and IgM antibodies using ELISA, as described previously 
[24]. Additionally, buffaloes were treated with triclaben-
dazole (1  ml, 5% per kilogram BW). After four weeks 
withdrawal time, 12 buffaloes in the infected group were 
infected orally with 500 viable metacercariae per animal, 
whereas control animals were mock-inoculated with 
0.85% NaCl solution without metacercariae [12].
Serum preparation and depletion of high abundance 
proteins
At 3, 42 and 70  days post-infection (dpi), whole blood 
samples of all animals in each group were collected asep-
tically into tubes without anticoagulant. Samples were 
allowed to clot and stored in a cooler on ice for up to 4 h 
post-collection before being centrifuged at 2500×g for 
10 min. Serum was collected and stored at −80 °C until 
use. Livers were collected after slaughter of animals and 
examined visually for gross pathological lesions. Highly-
abundant proteins were depleted using the ProteoM-
iner™ protein enrichment kit (Bio-Rad, Hercules, CA, 
USA) following the manufacturer’s instructions and pro-
tein concentration was determined by using a Bradford 
assay. Approximately 100  μg of protein of each sample 
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was digested with Trypsin Gold (Promega, Madison, WI, 
USA) at a ratio of 1:50 (trypsin to protein, wt/wt) at 37 °C 
overnight (~16 h). Digested peptides were desalted with a 
C18 cartridge to remove the high urea, and the desalted 
peptides were dried by vacuum centrifugation.
iTRAQ labeling of peptides
Desalted peptides were labeled with iTRAQ reagents 
 (iTRAQ® Reagent-8PLEX Multiplex Kit; Sigma, St. Louis, 
MO, USA) according to the manufacturer’s instructions. 
For 100  μg of peptides, 1 unit of labeling reagent was 
used. Peptides were dissolved in 20  μl of 0.5  M trieth-
ylammonium bicarbonate (TEAB) pH 8.5 solution and 
labeling reagent was added in 70 μl of isopropanol. After 
1 h of incubation, the reaction was stopped with 100 μl 
of 50 mM Tris-HCl pH 8. Differentially labeled peptides 
were mixed equally and then desalted in peptide desalt-
ing spin columns (Thermo Fisher Scientific, Waltham, 
MA, USA).
High performance liquid chromatography (HPLC) 
fractionation
The iTRAQ-labeled peptide mix was fractionated using a 
Durashell RP column (5 μm, 100 Å, 250 × 4.6 mm; Agela, 
Tianjin, China) on a Rigol L3000 HPLC (RIGOL SCIEN-
TIFIC, Allerød, Denmark) operating at 1 ml/min. Mobile 
phases A (2% acetonitrile, 20 mM NH4FA, adjusted pH 
to 10 using  NH3·H2O) and B (80% acetonitrile, 20 mM 
NH4FA, adjusted pH to 10 using  NH3·H2O) were used to 
develop a gradient elution. The tryptic peptides were sep-
arated at an eluent flow rate of 1 ml/min and monitored 
at 214 nm (UV). The column oven was set as 37 °C. Elu-
ent was collected every minute. The samples were dried 
under vacuum and reconstituted in 15  μl of 0.1% (v/v) 
formic acid (FA) in water for subsequent analysis.
LC‑MS/MS analysis
Shotgun proteomics analyses were performed using an 
EASY-nLCTM 1200 UHPLC system (Thermo Fisher Sci-
entific) coupled to an Orbitrap Fusion Lumos mass spec-
trometer (Thermo Fisher Scientific) operating in the 
data-dependent acquisition (DDA) mode. A sample vol-
ume corresponding to 2 μg of total peptides reconstituted 
in 0.1% FA was injected onto an Acclaim PepMap100 C18 
Nano-Trap column (2 cm × 100 μm, 5 μm; Dionex, Sun-
nyvale, USA). Peptides were separated on a Reprosil-Pur 
120 C18-AQ analytical column (15 cm × 150 μm, 1.9 μm; 
Dr. Maisch HPLC GmbH, Ammerbuch-Entringen, Ger-
many) using a 75 min linear gradient from 5 to 100% 
eluent B (0.1% FA in 80% acetonitrile) in eluent A (0.1% 
FA in  H2O) at a flow rate of 600  nl/min. For DDA, the 
Orbitrap Fusion Lumos mass spectrometer was operated 
in positive polarity mode with spray voltage of 2.3  kV 
and capillary temperature of 320 °C. Full mass spectrom-
etry (MS) scans from 300 to 1500 m/z were acquired at a 
resolution of 60,000 resolving power (at 200 m/z) with an 
AGC target value of 4 × 105 and a maximum ion injec-
tion time of 50  ms. The MS2 scans were acquired at a 
resolution of 15,000 resolving power (at 200 m/z) with an 
automatic gain control (AGC) target value of 5 × 104, a 
maximum ion injection time of 35 ms, and a normalized 
collision energy of 36%.
Protein identification
The MS raw data files (.wiff files) obtained from Triple-
TOF 5600 were submitted to ProteinPilot v.4.2 using 
the Paragon search engine against the Bos taurus pro-
tein database. To reduce the probability of false peptide 
identification, we counted only peptides at a cutoff value 
of 95% confidence interval by a ProteinPilot probability 
analysis greater than “identity” as identified, and each 
confident protein identification was supported by at least 
one unique peptide. Proteome Discoverer v.2.1 software 
was used to compare the quantitative data. We used 
ratios with P-values ≤ 0.05, and fold changes of ≥1.2 or 
≤0.83 were considered as significant.
Functional prediction
Three databases were used to predict gene and protein 
functions. These were GO (Gene Ontology, http://www.
geneo ntolo gy.org) [25], KEGG (Kyoto Encyclopedia of 
Genes and Genomes, http://www.genom e.jp/kegg/) [26, 
27] and COG (Clusters of Orthologous Groups, http://
www.ncbi.nlm.nih.gov/COG/) [28]. Fisher’s exact test 
followed by FDR correction [29] was performed to iden-
tify significantly enriched GO terms or pathways. The 
FDR corrected P-value < 0.05 was used as the threshold of 
significantly enriched.
Verification of proteomic results using parallel reaction 
monitoring (PRM)
A PRM assay allows sensitive and rapid analysis of pre-
selected proteins [30]. Therefore, PRM was applied to 
additional samples in order to verify protein expression 
patterns obtained by iTRAQ-based proteomic analysis. 
Briefly, protein preparation was performed as described 
above. Targeted MS analysis using PRM was per-
formed on a TripleTOF 5600+ LC-MS/MS system (AB 
SCIEX, Concord, ON). ProteinPilot software was used 
to identify proteins and peptide precursor ions for the 
DDA mode acquired raw data, and the database search 
results were analyzed using Skyline software v.4.2 to 
obtain a rough spectra library. Target proteins for PRM 
validation were imported into Skyline, and the peptides 
Page 4 of 11Zhang et al. Parasites Vectors          (2019) 12:281 
for protein quantification were selected according to 
the ion signals. The PRM method was run against the 
biological samples of interest, evaluated and refined to 
develop the highest quality assay. Data processing was 
performed in Skyline, and the results of the quantifica-
tion were manually inspected for each peptide of the 
targeted proteins.
Results
Confirmation of F. gigantica infection
At 70 dpi, livers collected from infected animals showed 
clear gross pathological lesions together with the pres-
ence of adult F. gigantica flukes, confirming the estab-
lishment of infection in all experimentally infected 
buffaloes. By contrast, livers of uninfected control buffa-
loes appeared normal, without any pathological changes 
and free of F. gigantica flukes.
Proteomics profiles of different groups
Proteomics analysis revealed 313, 459 and 399 serum 
proteins at 3, 42 and 70 dpi, respectively. Compared to 
control, 67, 67 and 113 proteins were significantly upreg-
ulated at 3, 42 and 72 dpi, respectively. However, a total 
of 25, 26 and 25 proteins showed significantly low expres-
sion levels in infected samples that were collected at 3, 42 
and 72 dpi, respectively (Figs. 1, 2 and Additional file 1: 
Table S1). E1BCJ2, E1BD43, F1MM86, F1N045, F2X047 
and Q9N2I2 were the most commonly differentially 
expressed protein at all time points after infection (3, 42 
and 72 dpi).
PRM validation of the protein expression in buffalo serum
Five significantly expressed proteins, including MHC 
class I antigen (UniProt identifier Q3YJH7), Beta-2-mi-
croglobulin (UniProt identifier P01888), NID2 protein 
(UniProt identifier A7E306), Fetuin-B (UniProt identi-
fier Q58D62) and Fibrinogen gamma-B chain (UniProt 
identifier P12799), were selected randomly and their 
Fig. 1 Venn diagram showing the unique and shared differentially 
expressed serum proteins between Fasciola gigantica‑infected animal 
groups at 3 (a), 42 (b) and 70 (c) days post‑infection
Fig. 2 Volcano plots showing the differentially expressed proteins detected in the serum of F. gigantica‑infected compared to uninfected control 
buffaloes. The most statistically significant proteins are shown toward the top, with upregulated proteins in red dots and downregulated proteins in 
green dots. Black dots represent no significant differences. The x‑axis represents  log2(fold change) values and y‑axis represents −log10(pval) values. 
a, b and c represent differentially expressed proteins at 3, 42 and 70 days post‑infection, respectively
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expression was examined by PRM. The trends of the level 
of expression of these five proteins obtained by iTRAQ 
and PRM were similar (Fig. 3).
Cluster of Orthologous Groups of proteins (COG) analysis
All identified proteins were classified into 23 COG clus-
ters including energy production and conversion, cell 
cycle control, cell division, chromosome partitioning, 
and amino acid transport and metabolism. Among these, 
matched proteins in “posttranslational modification, pro-
tein turnover, chaperones” accounted for the largest pro-
portion in all COG. Matched proteins in COG function 
classification are shown in Fig. 4.
GO classification and KEGG analysis
GO classification was performed to study the biological 
function of the identified proteins in the buffalo sera. The 
identified proteins were classified into “molecular func-
tion”, “biological process” and “cellular component” as 
shown in Fig.  5. Most proteins were involved in molec-
ular functions that are essential for biological activities. 
According to KEGG analysis, 6 sections containing 39 
pathways were identified in the buffalo sera as shown in 
Fig.  6. “signal transduction” in “environmental informa-
tion processing”, “infectious diseases” and “cardiovascular 
diseases” in “human diseases”, and “immune system” in 
“organismal systems” were significantly highly enriched 
compared to other maps. Most of the differentially 
expressed proteins were enriched in immune system and 
infection diseases. 
Fig. 3 PRM verification of proteins identified by iTRAQ analysis. Five 
proteins were selected for validation of the iTRAQ data. Data of iTRAQ 
were verified by PRM at 3 (a), 42 (b) and 70 (c) days post‑infection, 
respectively
Fig. 4 COG function classification. The x‑axis represents the function’s class and the y‑axis shows the number of matched proteins
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Fig. 5 GO annotation of all identified proteins. Identified proteins in all three groups were stratified into three categories: molecular function, 
cellular component and biological process
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Heatmap clustering of identified proteins in buffalo serum
All identified proteins were clustered according to the 
expression data. As shown in Fig.  7, at each time point 
the infected samples and control samples were clustered 
into different branches. The identified proteins at each 
time point had significantly different expression pattern 
between control and infected group.
Discussion
The mechanisms whereby F. gigantica influences the 
serum proteome of buffaloes have not yet been fully 
elucidated. In this study, we employed the iTRAQ tech-
nique to uncover the global serum proteomic changes 
in buffaloes infected with F. gigantica. Our results 
showed that the serum protein profiles of infected 
buffaloes and non-infected buffaloes were clearly sep-
arated (Fig.  7). In the present study, F. gigantica influ-
enced the expression of serum proteins associated with 
protein binding, immune systems and signal transduc-
tion. Our iTRAQ-based proteomics analysis revealed 
92, 93 and 138 differentially expressed proteins at 3, 
42 and 70 dpi, respectively (Additional file 1: Table S1 
and Fig.  2). iTRAQ results were validated by re-test-
ing the expression of five proteins using PRM. Results 
obtained by iTRAQ had a similar expression trend with 
PRM (Fig.  3), suggesting the reliability of our iTRAQ 
analysis.
Fig. 6 Statistics of KEGG pathway annotation. The x‑axis shows the number of proteins; the y‑axis corresponds to KEGG pathway annotation
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After newly excysted juveniles emerge in the duode-
num of the definitive host, they migrate across the perito-
neum to the liver and eventually to the bile duct. During 
this journey juvenile flukes feed on the host blood and 
undergo maturation to egg-laying adult flukes [31]. Addi-
tionally, they must adapt to different host microenviron-
ments and engage in various biological processes, such as 
blood coagulation and complement activation. In the fol-
lowing sections, we discuss the influence of F. gigantica 
on blood coagulation, complement activation, and other 
immune response mechanisms in buffalo serum.
Fasciola gigantica influences coagulation and platelet 
activation
Protein C inhibitor (PCI or SERPINA5) participates in 
many biological progresses including its diverse roles 
in blood coagulation as a pro- and anti-coagulant factor 
[32]. At 3 dpi, PCI was significantly upregulated com-
pared to control buffaloes. Due to its dual roles in coagu-
lation, we can hypothesize that F. gigantica utilizes PCI’s 
anti-coagulant property instead of pro-coagulant abil-
ity in order to ensure enough blood for the feeding of 
juvenile flukes. The downregulation of C5 and upregu-
lation of PCI at 42 dpi suggest that F. gigantica reduces 
coagulation of buffalo blood to maintain enough food for 
the development of the growing flukes. At 70  dpi, PCI 
expression was reduced, suggesting that chronic F. gigan-
tica infection may enhance the host coagulation process. 
These findings indicate that there are two distinct pro-
cesses involved in host coagulative responses to fluke 
infection and that those mechanisms may be differen-
tially affected by stage of infection.
Platelets play an essential role in the hemostatic pro-
cess, and not only contribute to the formation of the 
primary plug, but also accelerate coagulation [33]. Prior 
research has shown that several classes of surface glyco-
proteins are essential for primary platelet responses [33] 
and different proteins and glycoproteins are expressed 
at the surface of F. gigantica. Thus, there is a reason to 
believe that F. gigantica can manipulate the platelet acti-
vation pathway in buffaloes during infection. P12799 
(fibrinogen gamma chain, gene name: FGG) was down-
regulated at 70 dpi. Together with fibrinogen alpha (FGA) 
and fibrinogen beta (FGB), FGG polymerizes to form 
an insoluble fibrin matrix [34], which is one of the pri-
mary components of blood clots [35]. Furthermore, FGG 
encoding protein functions during early stages of wound 
repair to stabilize the lesion and guide cell migration 
during re-epithelialization [36]. The downregulation of 
FGG can reduce the formation of blood clots and platelet 
aggregation in buffaloes infected with F. gigantica, which 
may make blood more accessible to the flukes. On the 
other hand, upregulation of F1MAV0, F1MDH3, P60712, 
P61223 and Q32LP0 can lead to platelet activation. 
Therefore, excess platelets and less clotting may be one 
of the mechanism that underpin hemorrhagic anaemia in 
hosts infected with liver flukes
The complement system and F. gigantica infection
E1BCJ2 (gene name: CFHR5, complement factor H 
related 5), E1BD43 (gene name: AOC3, protein name: 
amine oxidase involved in lymphocyte binding), 
F1MM86 (gene name: C6; protein name: complement 
component C6 involved in the regulation of comple-
ment cascade), F1N045 (gene name: C7; protein name: 
complement component C7), F2X047 (gene name: LYZ; 
protein name: lysozyme involved in hydrolysis signaling 
pathway), and Q9N2I2 (gene name: SERPINA5; protein 
Fig. 7 Heatmaps of the differentially expressed proteins. a, b and c show the differentially expressed proteins at 3, 42 and 70 days post‑infection, 
respectively. The red (upregulated) and blue (downregulated) colors represent the differentially expressed proteins; the white color represents the 
proteins whose expression levels were not different from control, uninfected samples
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name: plasma serine protease inhibitor) were differen-
tially expressed in sera of infected buffaloes at all three 
time points after infection.
Previous studies have investigated the role of Th2 
[12], Th1/Th17 [23], cytokines [14] and antibody [37] 
responses in the immunopathogenesis of F. gigantica. 
However, reports about complement component changes 
during F. gigantica infection are limited. This is the first 
report, to our knowledge, of the involvement of buffalo 
complement components at different phases of F. gigan-
tica infection. F1MM86 (C6) and F1N045 (C7) with C5b, 
C8 (F1MX87) and multiple copies of C9 (Q3MHN2) are 
complement components of the membrane attack com-
plex (MAC), which is known to compromise osmotic 
integrity and induce cell death in pathogens [38]. 
F1MM86 and F1N045 showed similar trends during 
infection with significantly high expression at early (3 dpi) 
and late (70 dpi) infection. A previous study showed that 
a F. gigantica-specific antibody that promotes the activa-
tion of complement cascade pathway was increased from 
3 weeks post-infection (wpi) and peaked at 13 wpi [37]. 
This result suggests that F. gigantica can modulate the 
buffalo’s immune responses, especially the complement 
system to promote its survival and persistence in the liver 
of buffaloes. The influence of F. hepatica on the comple-
ment activation pathways has been also reported [39].
The classical pathway of complement activation is part 
of the adaptive immune response and is initiated with 
antibody binding [40]. The lectin pathway and the alter-
native pathway are two complement pathways, which are 
independent of antibody-antigen interaction [41]. The 
lection pathway is initiated by carbohydrates on micro-
bial surfaces [42, 43] and the alternative pathway can be 
initiated by blood-coagulation [44]. Given the upregula-
tion of F1MM86 and F1N045 at 3 and 70 dpi, we infer 
that lectin and carbohydrate on the surface of F. gigan-
tica, and specific host antibody can promote the comple-
ment responses at 70  dpi. This is the first report of the 
influence of F. gigantica on the complement in buffaloes.
Fasciola gigantica affects recruitment of lymphocytes
Vascular adhesion protein-1 (VAP-1, also called amine 
oxidase copper containing-3 [AOC3]), is an endothe-
lial cell adhesion molecule that promotes recruitment of 
lymphocytes, such as  CD8+ T cells,  CD4+ T cells and NK 
cells to the liver [45]. The granulocyte adhesion to VAP-1 
is mediated by Siglec-9 [46, 47]. VAP-1 is constitutively 
expressed in the sinusoids of human liver and is activated 
during an immune response [48], especially in inflamma-
tory liver disease [49]. The expression of VAP-1 has been 
also associated with various tumors, such as astrocytoma 
[50], colorectal cancer [51], gastric cancer [52] and breast 
cancer [53].
At 3 and 42 dpi, F. gigantica induces an inflammatory 
response and enhances VAP-1 homing of lymphocytes 
to liver, but in the meantime the fluke attenuates inflam-
matory responses by downregulating lipopolysaccharide 
binding protein (LBP) to promote its own survival [12]. 
At 70  dpi, there was a significant downregulation of 
VAP-1 in the buffalo sera. It is possible that VAP-1 plays 
roles that can be compensated for by other molecules. 
For example, activated immune responses mediated by 
TLRs and NLRs were previously reported in buffalo liv-
ers at 70 dpi with F. gigantica [23]. These findings indicate 
that in the course of F. gigantica infection, coordinated 
pro- and anti-inflammatory signals allow the flukes to 
evade the host immune control and prevent excessive 
inflammatory response from inducing extensive tissue 
damage in order to favor parasite persistence.
Lysozyme hydrolyzes glycosphingolipids in F. gigantica
The upregulation of lysozyme at 3, 42 and 70  dpi indi-
cates that buffaloes may activate lysosome in response 
to F. gigantica as part of the antiparasitic defense strat-
egies to damage the fluke’s structural integrity via tar-
geting glycosphingolipids. Lysozymes are key players 
of the innate immune system and possess antimicrobial 
activity [54]. The lysozyme catalyzes the hydrolysis of 
1,4-beta-linkage between N-acetylmuramic acid and 
N-acetyl-D-glucosamine in peptidoglycans and between 
the N-acetyl-D-glucosamine residues in chitodextrins 
[55]. A previous study found no link between lysozyme 
and F. hepatica [56]. However, F. hepatica expresses the 
globo-series of glycosphingolipids [Gal(α1-4)Gal(β1-4)
Glc(β1-1)Cer] [57] and glycosphingolipids isolated from 
F. hepatica and F. gigantica [58] are a subtype of glycolip-
ids, containing the amino alcohol sphingosine, and there 
is a 1,4-beta linkage between galactose and glucose. The 
presence of a 1,4-beta linkage between these two mole-
cules indicate that lysozyme may hydrolyze glycosphin-
golipids in F. gigantica and F. hepatica.
Conclusions
In the present study, the iTRAQ-based proteomics 
technique coupled with a parallel reaction monitor-
ing approach was used to identify the differentially 
abundant proteins in the serum of F. gigantica-infected 
versus control buffaloes. A total of 313, 459 and 399 pro-
teins were identified at 3, 42 and 70 days post-infection, 
respectively; of these 92, 93 and 138 were differentially 
abundant proteins. The most significant differentially 
abundant protein markers that distinguished sera of 
infected from uninfected buffaloes included complement 
factor H related 5, complement component C6, comple-
ment component C7, amine oxidase, plasma serine pro-
tease inhibitor and lysozyme, which are known to be 
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involved in complement system activation, blood coag-
ulation, platelet activation, lymphocyte adhesion and 
lysozyme hydrolysis. Further characterization of buffalo 
proteins involved in the pathogenesis of F. gigantica may 
lead to the discovery of novel therapeutic or diagnostic 
targets.
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